Publication: Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy.
Loading...
Identifiers
Date
2021-08-03
Authors
Partridge, Ann H
Niman, Samuel M
Ruggeri, Monica
Peccatori, Fedro A
Azim, Hatem A
Colleoni, Marco
Saura, Cristina
Shimizu, Chikako
Sætersdal, Anna Barbro
Kroep, Judith R
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study investigates the impact of temporary ET interruption to allow pregnancy. POSITIVE enrolled women with stage I-III HR + early breast cancer, ≤42 years, who had received 18-30 months of adjuvant ET and wished to interrupt ET for pregnancy. Treatment interruption for up to 2 years was permitted to allow pregnancy, delivery and breastfeeding, followed by ET resumption to complete the planned duration. From 12/2014 to 12/2019, 518 women were enrolled at 116 institutions/20 countries/4 continents. At enrolment, the median age was 37 years and 74.9 % were nulliparous. Fertility preservation was used by 51.5 % of women. 93.2 % of patients had stage I/II disease, 66.0 % were node-negative, 54.7 % had breast conserving surgery, 61.9 % had received neo/adjuvant chemotherapy. Tamoxifen alone was the most prescribed ET (41.8 %), followed by tamoxifen + ovarian function suppression (OFS) (35.4 %). A greater proportion of North American women were The characteristics of participants in the POSITIVE study provide insights to which patients and doctors considered it acceptable to interrupt ET to pursue pregnancy. Similarities and variations from a regional, sociodemographic, disease and treatment standpoint suggest specific sociocultural attitudes across the world.
Description
MeSH Terms
Adult
Antineoplastic Agents, Hormonal
Breast Neoplasms
Cancer Survivors
Chemotherapy, Adjuvant
Female
Hormones
Humans
Mastectomy
Pregnancy
Premenopause
Tamoxifen
Antineoplastic Agents, Hormonal
Breast Neoplasms
Cancer Survivors
Chemotherapy, Adjuvant
Female
Hormones
Humans
Mastectomy
Pregnancy
Premenopause
Tamoxifen
DeCS Terms
CIE Terms
Keywords
Breast cancer, Endocrine therapy, Pregnancy desire, Premenopausal women, Treatment interruption, Young women